Cosmo Pharmaceuticals N.V (C43) — Cash Flow Reinvestment Rate
Cosmo Pharmaceuticals N.V (C43) has a Cash Flow Reinvestment Rate of 3.04x as of June 2022, reinvesting €19.08 Million (capex €1.11 Million plus investments €17.98 Million) from operating cash flow of €6.28 Million. Check Cosmo Pharmaceuticals N.V earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cosmo Pharmaceuticals N.V Cash Flow Reinvestment Rate (2016–2024)
Historical reinvestment intensity for Cosmo Pharmaceuticals N.V across 6 annual periods. Explore Cosmo Pharmaceuticals N.V (C43) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Cosmo Pharmaceuticals N.V (2016–2024)
Year-by-year capital reinvestment analysis for Cosmo Pharmaceuticals N.V. For live market cap and broader valuation context, see Cosmo Pharmaceuticals N.V (C43) total market value.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.79x | €129.11 Million | €162.41 Million | €5.65 Million | ▼ -53.6% |
| 2023 | 1.71x | €57.61 Million | €33.62 Million | €15.31 Million | ▲ +532.7% |
| 2022 | 0.27x | €9.00 Million | €33.23 Million | €7.31 Million | ▼ -72.1% |
| 2021 | 0.97x | €12.22 Million | €12.61 Million | €5.49 Million | ▼ -88.7% |
| 2020 | 8.59x | €111.60 Million | €12.98 Million | €4.12 Million | ▲ +217.9% |
| 2016 | 2.70x | €58.65 Million | €21.69 Million | €18.43 Million | — |